Mabion S.A. (MAB) - Total Assets
Based on the latest financial reports, Mabion S.A. (MAB) holds total assets worth zł109.85 Million PLN (≈ $30.23 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore MAB debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Mabion S.A. - Total Assets Trend (2009–2025)
This chart illustrates how Mabion S.A.'s total assets have evolved over time, based on quarterly financial data. See MAB book value for net asset value and shareholders' equity analysis.
Mabion S.A. - Asset Composition Analysis
Current Asset Composition (December 2025)
Mabion S.A.'s total assets of zł109.85 Million consist of 11.6% current assets and 88.4% non-current assets.
| Asset Category | Amount (PLN) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 5.8% |
| Accounts Receivable | zł1.91 Million | 1.7% |
| Inventory | zł1.41 Million | 1.3% |
| Property, Plant & Equipment | zł0.00 | 0.0% |
| Intangible Assets | zł159.00K | 0.1% |
| Goodwill | zł0.00 | 0.0% |
Asset Composition Trend (2009–2025)
This chart illustrates how Mabion S.A.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see MAB market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Mabion S.A.'s current assets represent 11.6% of total assets in 2025, a decrease from 59.4% in 2009.
- Cash Position: Cash and equivalents constituted 5.8% of total assets in 2025, up from 1.5% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2009.
- Asset Diversification: The largest asset category is accounts receivable at 1.7% of total assets.
Mabion S.A. Competitors by Total Assets
Key competitors of Mabion S.A. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Sk Biopharmaceuticals Co Ltd
KO:326030
|
Korea | ₩1.20 Trillion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $398.69 Million |
|
TELIX Pharmaceuticals Ltd
AU:TLX
|
Australia | AU$1.19 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Theravance Biopharma Inc
F:0TB
|
Germany | €415.46 Million |
Mabion S.A. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.31 | 0.82 | 1.20 |
| Quick Ratio | 0.28 | 0.75 | 1.16 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | zł-31.96 Million | zł-6.77 Million | zł24.54 Million |
Mabion S.A. - Advanced Valuation Insights
This section examines the relationship between Mabion S.A.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.00 |
| Latest Market Cap to Assets Ratio | 0.30 |
| Asset Growth Rate (YoY) | -30.8% |
| Total Assets | zł110.43 Million |
| Market Capitalization | $33.41 Million USD |
Valuation Analysis
Below Book Valuation: The market values Mabion S.A.'s assets below their book value (0.30x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Mabion S.A.'s assets decreased by 30.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Mabion S.A. (2009–2025)
The table below shows the annual total assets of Mabion S.A. from 2009 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | zł110.43 Million ≈ $30.39 Million |
-30.75% |
| 2024-12-31 | zł159.47 Million ≈ $43.89 Million |
-23.42% |
| 2023-12-31 | zł208.25 Million ≈ $57.31 Million |
+11.86% |
| 2022-12-31 | zł186.18 Million ≈ $51.24 Million |
+1.05% |
| 2021-12-31 | zł184.24 Million ≈ $50.70 Million |
+135.23% |
| 2020-12-31 | zł78.32 Million ≈ $21.56 Million |
-31.02% |
| 2019-12-31 | zł113.55 Million ≈ $31.25 Million |
-21.54% |
| 2018-12-31 | zł144.72 Million ≈ $39.83 Million |
+75.53% |
| 2017-12-31 | zł82.44 Million ≈ $22.69 Million |
-9.65% |
| 2016-12-31 | zł91.25 Million ≈ $25.11 Million |
-52.86% |
| 2015-12-31 | zł193.55 Million ≈ $53.27 Million |
-86.93% |
| 2014-12-31 | zł1.48 Billion ≈ $407.64 Million |
+96.26% |
| 2013-12-31 | zł754.68 Million ≈ $207.70 Million |
-80.97% |
| 2012-12-31 | zł3.97 Billion ≈ $1.09 Billion |
+14620.07% |
| 2011-12-31 | zł26.94 Million ≈ $7.41 Million |
+14.95% |
| 2010-12-31 | zł23.44 Million ≈ $6.45 Million |
+6632.39% |
| 2009-12-31 | zł348.15K ≈ $95.82K |
-- |
About Mabion S.A.
Mabion S.A., a biopharmaceutical company, provides services as a contract development and manufacturing organization in the process development, analytics, and manufacturing of biologic medicines in Poland. It offers drug substance manufacturing, fill and finish, gene to vial end-to-end development, process development, analytics, and banking services. In addition, it offers cell line development… Read more